image
Healthcare - Medical - Instruments & Supplies - NASDAQ - US
$ 1.11
-17.2 %
$ 9.91 M
Market Cap
-0.56
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one POAI stock under the worst case scenario is HIDDEN Compared to the current market price of 1.11 USD, Predictive Oncology Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one POAI stock under the base case scenario is HIDDEN Compared to the current market price of 1.11 USD, Predictive Oncology Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one POAI stock under the best case scenario is HIDDEN Compared to the current market price of 1.11 USD, Predictive Oncology Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart POAI

image
$2.0$2.0$1.8$1.8$1.6$1.6$1.4$1.4$1.2$1.2$1.0$1.0$0.8$0.8$0.6$0.6$0.4$0.415 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
1.62 M REVENUE
-8.78%
-10.9 M OPERATING INCOME
22.89%
-12.7 M NET INCOME
9.44%
-11 M OPERATING CASH FLOW
16.79%
-9.51 K INVESTING CASH FLOW
96.85%
3.94 M FINANCING CASH FLOW
2545.57%
612 K REVENUE
76.92%
-2.12 M OPERATING INCOME
8.23%
-2.1 M NET INCOME
32.11%
-2.06 M OPERATING CASH FLOW
9.59%
0 INVESTING CASH FLOW
0.00%
-196 K FINANCING CASH FLOW
-22.04%
Balance Sheet Predictive Oncology Inc.
image
Current Assets 2.23 M
Cash & Short-Term Investments 735 K
Receivables 746 K
Other Current Assets 746 K
Non-Current Assets 2.75 M
Long-Term Investments 0
PP&E 2.43 M
Other Non-Current Assets 313 K
14.77 %14.99 %15.00 %48.95 %6.29 %Total Assets$5.0m
Current Liabilities 3.59 M
Accounts Payable 1.14 M
Short-Term Debt 573 K
Other Current Liabilities 1.88 M
Non-Current Liabilities 1.58 M
Long-Term Debt 1.56 M
Other Non-Current Liabilities 23.5 K
22.08 %11.07 %36.28 %30.11 %Total Liabilities$5.2m
EFFICIENCY
Earnings Waterfall Predictive Oncology Inc.
image
Revenue 1.62 M
Cost Of Revenue 826 K
Gross Profit 798 K
Operating Expenses 11.7 M
Operating Income -10.9 M
Other Expenses 1.8 M
Net Income -12.7 M
2m2m00(2m)(2m)(4m)(4m)(6m)(6m)(8m)(8m)(10m)(10m)(12m)(12m)(14m)(14m)2m(826k)798k(12m)(11m)(2m)(13m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
49.12% GROSS MARGIN
49.12%
-668.81% OPERATING MARGIN
-668.81%
-779.91% NET MARGIN
-779.91%
6250.62% ROE
6250.62%
-254.69% ROA
-254.69%
-556.40% ROIC
-556.40%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Predictive Oncology Inc.
image
00(2m)(2m)(4m)(4m)(6m)(6m)(8m)(8m)(10m)(10m)(12m)(12m)(14m)(14m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -12.7 M
Depreciation & Amortization 696 K
Capital Expenditures -9.51 K
Stock-Based Compensation 0
Change in Working Capital 0
Others 994 K
Free Cash Flow -11 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Predictive Oncology Inc.
image
POAI has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 10
6. Ownership
Insider Ownership Predictive Oncology Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Predictive Oncology Reports Year-End 2024 Financial Results and Provides Corporate Update PITTSBURGH, April 01, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, and CLIA laboratory, to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the quarter ended December 31, 2024, and provided a corporate update. The Company reported a loss from continuing operations of approximately $10.8 million on total revenue of $1.6 million for the year ended December 31, 2024. globenewswire.com - 2 weeks ago
Predictive Oncology Successfully Develops Predictive Models Derived from Never-Before-Seen Compounds for Prevalent Cancer Indications Including Breast, Colon and Ovary Company successfully developed predictive models derived from 21 unique compounds from the Natural Products Discovery Core at the University of Michigan globenewswire.com - 3 weeks ago
Predictive Oncology Completes Sale of Skyline Medical Assets to DeRoyal Industries Deal positions STREAMWAY ® Systems with an established market leader to drive accelerating growth globenewswire.com - 1 month ago
Predictive Oncology Closes Registered Direct Offering PITTSBURGH, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or the “Company”), a leader in AI-driven drug discovery and biologics, today closed its previously announced registered direct offering for the purchase and sale of 363,336 shares of common stock at a purchase price of $1.50 per share priced at-the-market under Nasdaq rules. globenewswire.com - 1 month ago
Predictive Oncology Reports Positive Results Utilizing Artificial Intelligence for Drug Repurposing Company successfully identified several abandoned or discontinued drugs for further testing and development in ovarian and other cancer types globenewswire.com - 2 months ago
Certis Oncology Announces Issuance of U.S. Patent for Its Proprietary CertisAI Predictive Oncology Intelligence™ Platform SAN DIEGO--(BUSINESS WIRE)-- #CertisAI--Certis Oncology Solutions, a precision oncology and translational science company, announced today that the United States Patent and Trademark Office (USPTO) has allowed a patent application directed to Certis's predictive artificial intelligence/machine learning (AI/ML) platform, CertisAI™. “The patent marks an important milestone for our company,” said Peter Ellman, President and CEO of Certis. “It substantiates the uniqueness of our proprietary platform and the un. businesswire.com - 2 months ago
Predictive Oncology Announces Planned European Launch of its ChemoFx® Treatment Selection Marker and Tumor Profiling Assay Initial plans target European clinical trials while providing standard testing to clinicians for individual patients There are an estimated 250,000 gynecologic cancers diagnosed annually across Europe PITTSBURGH, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, today announced plans to launch its validated flagship live cell ChemoFx® drug response assay in Europe and expanded availability in the United States. The ChemoFx® treatment selection marker and tumor profiling assay will initially focus on ovarian and other gynecological cancers and may include testing of other major tumor types of interest over time. globenewswire.com - 3 months ago
PREDICTIVE ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Predictive Oncology Inc. - POAI NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Predictive Oncology Inc. (NasdaqCM: POAI) to Renovaro Inc. (NasdaqCM: RENB). Under the terms of the binding letter of intent, Predictive Oncology will be merged into Renovaro in exchange for a newly created series of preferred stock of Renovaro. The preferred stock will be issued to shareholders of Predictive. businesswire.com - 3 months ago
POAI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Predictive Oncology Inc. Is Fair to Shareholders NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Predictive Oncology Inc. (NASDAQ: POAI) to Renovaro Inc. is fair to Predictive shareholders. Halper Sadeh encourages Predictive shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Predictive and its board of direct. businesswire.com - 3 months ago
Renovaro to Acquire Predictive Oncology in All-Stock Transaction Acquisition provides access to critical resources encompassing a biobank of more than 150,000 tumor specimens, 200,000 pathology slides and decades of longitudinal drug response data Data provides a critical pathway to progress AI using the high-speed computing power provided through collaboration with Nebul Combines Predictive Oncology's AI-driven multi-omic drug discovery platform with Renovaro's AI Cube multi-omic artificial intelligence to advance both cancer diagnostics and early drug discovery Planned test launch to assist physicians in individualizing cancer therapy to improve treatment outcomes LOS ANGELES, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today announced it has entered into a binding LOI to acquire Predictive Oncology (NASDAQ: POAI) in an all-stock transaction. David Weinstein, Chief Executive Officer of Renovaro, commented, “Renovaro is on a quest to offer cancer patients early diagnostic options, treatment protocols, and recurrence monitoring. globenewswire.com - 3 months ago
Predictive Oncology Announces Agreement to be Acquired by Renovaro - Combination creates immediate scientific synergies by harnessing complementary AI / ML platforms to improve patient outcomes across multiple cancer indications – globenewswire.com - 3 months ago
Predictive Oncology Reports Third Quarter 2024 Financial Results and Provides Strategic Update Company initiates process to explore a broad range of strategic alternatives to maximize shareholder value Company initiates process to explore a broad range of strategic alternatives to maximize shareholder value globenewswire.com - 5 months ago
8. Profile Summary

Predictive Oncology Inc. POAI

image
COUNTRY US
INDUSTRY Medical - Instruments & Supplies
MARKET CAP $ 9.91 M
Dividend Yield 0.00%
Description Predictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States. The company operates in four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment offers clinical testing services comprising tumor drug response testing and genomic profiling tests; and contract research services through patient-centric drug discovery using active learning technology for discovery, clinical and translational research, clinical trials, and diagnostic development and validation. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using High-Throughput Self-Interaction Chromatography, a self-contained, automated system that conducts high-throughput, self-interaction chromatography screens using additives and excipients that are included in protein formulations for soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates staff exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. It also offers research and development services; and media that help cancer cells grow outside the patient's body and retain their DNA/RNA and proteomic signatures. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota.
Contact 2915 Commers Drive, Eagan, MN, 55121 https://www.predictive-oncology.com
IPO Date May 3, 2010
Employees 34
Officers Dr. Lawrence J. DeLucas D.Sc, O.D, Ph.D. Senior Vice President of Biologics Dr. Arlette H. Uihlein FCAP, M.D. Senior Vice President of Translational Medicine & Drug Discovery and Medical Director